The University of Southampton
University of Southampton Institutional Repository

FRAX and the effect of teriparatide on vertebral and non-vertebral fracture

FRAX and the effect of teriparatide on vertebral and non-vertebral fracture
FRAX and the effect of teriparatide on vertebral and non-vertebral fracture
Background: daily administration of 20µg or 40µg teriparatide has been shown to significantly decrease the risk of vertebral and non-vertebral fracture compared with placebo. The aim of the present study was to evaluate fracture risk assessed at baseline using the FRAX® tool and to determine the efficacy of teriparatide as a function of baseline fracture risk.

Methods: 1637 postmenopausal women in the pivotal phase 3 trial, randomly assigned to receive placebo (n=544), teriparatide 20 ?g per day (n=541) or teriparatide 40 ?g per day (n=552), were studied. Baseline clinical risk factors were entered into country-specific FRAX models to compute the 10-year probability of major osteoporotic fractures with or without input of femoral neck BMD. Because there was no difference in effect of 20 and 40?g teriparatide daily on fracture occurrence, the two active groups were merged. The interaction between probability of a major fracture and treatment efficacy was examined by Poisson regression.

Results: the 10-year probability of major osteoporotic fractures (with BMD) ranged from 2.2-67.2%. Treatment with teriparatide was associated with a 37% decrease in all non-vertebral fractures (95% CI:10-56 %) and a 56% decrease in low energy non-vertebral fractures (95% CI:24-75%) compared with placebo. The risk of morphometric vertebral fractures decreased significantly by 66% (95% CI:50-77%). Hazard ratios for the effect of teriparatide on the fracture outcome did not change significantly with increasing fracture probability (p>0.30). Similar findings were noted for the interaction when BMD was excluded from the FRAX model, or when probability of hip fracture was used as the marker of baseline risk.

Conclusion: we conclude that teriparatide significantly decreases the risk of non-vertebral and morphometric vertebral fractures in women by a similar extent, irrespective of baseline fracture probability


FRAX, teriparatide, osteoporosis, epidemiology, fracture, interaction, BMD, randomised controlled trial
0937-941X
Harvey, Nicholas C.
ce487fb4-d360-4aac-9d17-9466d6cba145
Kanis, John A.
f1621d8d-8afb-4d97-9679-2165d88a344d
Odén, Anders
cc56db15-a8d7-40f3-bd92-59d7a9abbf62
Burge, Russel T.
1bc911c6-3cca-4364-ac00-168214ca883d
Mitlak, Bruce H.
87a42948-037b-4fd6-a39b-40d48cfa318c
Johansson, Helena
04f12338-4dd1-437b-b9bc-e0884130c215
McCloskey, Eugene
3a2fac33-b400-4ae3-a212-04c3c3d2a517
Harvey, Nicholas C.
ce487fb4-d360-4aac-9d17-9466d6cba145
Kanis, John A.
f1621d8d-8afb-4d97-9679-2165d88a344d
Odén, Anders
cc56db15-a8d7-40f3-bd92-59d7a9abbf62
Burge, Russel T.
1bc911c6-3cca-4364-ac00-168214ca883d
Mitlak, Bruce H.
87a42948-037b-4fd6-a39b-40d48cfa318c
Johansson, Helena
04f12338-4dd1-437b-b9bc-e0884130c215
McCloskey, Eugene
3a2fac33-b400-4ae3-a212-04c3c3d2a517

Harvey, Nicholas C., Kanis, John A., Odén, Anders, Burge, Russel T., Mitlak, Bruce H., Johansson, Helena and McCloskey, Eugene (2015) FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. Osteoporosis International. (In Press)

Record type: Article

Abstract

Background: daily administration of 20µg or 40µg teriparatide has been shown to significantly decrease the risk of vertebral and non-vertebral fracture compared with placebo. The aim of the present study was to evaluate fracture risk assessed at baseline using the FRAX® tool and to determine the efficacy of teriparatide as a function of baseline fracture risk.

Methods: 1637 postmenopausal women in the pivotal phase 3 trial, randomly assigned to receive placebo (n=544), teriparatide 20 ?g per day (n=541) or teriparatide 40 ?g per day (n=552), were studied. Baseline clinical risk factors were entered into country-specific FRAX models to compute the 10-year probability of major osteoporotic fractures with or without input of femoral neck BMD. Because there was no difference in effect of 20 and 40?g teriparatide daily on fracture occurrence, the two active groups were merged. The interaction between probability of a major fracture and treatment efficacy was examined by Poisson regression.

Results: the 10-year probability of major osteoporotic fractures (with BMD) ranged from 2.2-67.2%. Treatment with teriparatide was associated with a 37% decrease in all non-vertebral fractures (95% CI:10-56 %) and a 56% decrease in low energy non-vertebral fractures (95% CI:24-75%) compared with placebo. The risk of morphometric vertebral fractures decreased significantly by 66% (95% CI:50-77%). Hazard ratios for the effect of teriparatide on the fracture outcome did not change significantly with increasing fracture probability (p>0.30). Similar findings were noted for the interaction when BMD was excluded from the FRAX model, or when probability of hip fracture was used as the marker of baseline risk.

Conclusion: we conclude that teriparatide significantly decreases the risk of non-vertebral and morphometric vertebral fractures in women by a similar extent, irrespective of baseline fracture probability


Text
PTH FRAX Lilly nch 27022015.docx - Accepted Manuscript
Download (70kB)

More information

Accepted/In Press date: 10 May 2015
Keywords: FRAX, teriparatide, osteoporosis, epidemiology, fracture, interaction, BMD, randomised controlled trial
Organisations: Human Development & Health

Identifiers

Local EPrints ID: 377284
URI: http://eprints.soton.ac.uk/id/eprint/377284
ISSN: 0937-941X
PURE UUID: 9e4ce4fd-42c9-4a4c-9846-b060e20e0c61
ORCID for Nicholas C. Harvey: ORCID iD orcid.org/0000-0002-8194-2512

Catalogue record

Date deposited: 28 May 2015 13:30
Last modified: 15 Mar 2024 03:19

Export record

Contributors

Author: John A. Kanis
Author: Anders Odén
Author: Russel T. Burge
Author: Bruce H. Mitlak
Author: Helena Johansson
Author: Eugene McCloskey

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×